Next Century Growth Investors’s Apyx Medical APYX Stock Holding History

Next Century Growth Investors’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-341,146	Closed	-$1.53M	–	104
2022 Q3	$1.53M	Sell	341,146 -255,150	-43%	-$1.83M	0.19%	84
2022 Q2	$3.49M	Buy	+596,296	New	+$3.06M	0.46%	58

Other funds holding APYX

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Next Century Growth Investors's APYX Position: Q4 2022 in Review

Next Century Growth Investors sold out of Apyx Medical (APYX) in Q4 2022, closing a stake of 341,146 shares — an estimated $1.53M sold.

Next Century Growth Investors first reported a position in APYX in Q2 2022 and held it in 2 quarters. The position peaked at $3.49M in Q2 2022. 51 funds tracked by Wall St. Rank hold APYX as of Q4 2022.

Next Century Growth Investors reported no remaining Apyx Medical position as of Q4 2022 after selling out during the quarter.
Next Century Growth Investors sold 341,146 Apyx Medical shares in Q4 2022, an estimated $1.53M.
Next Century Growth Investors first reported a position in Apyx Medical in Q2 2022 and held it in 2 quarters.
Next Century Growth Investors's Apyx Medical position peaked at $3.49M in Q2 2022.
51 funds tracked by Wall St. Rank held Apyx Medical as of Q4 2022.

Based on Next Century Growth Investors's 13F filing for Q4 2022, filed 14 Feb 2023.